
New Drug Achieves 100% Success in Treating Bowel Cancer
An immunotherapy drug, Jemperli (dostarlimab) from GSK, has shown unprecedented results in treating locally advanced mismatch repair deficient (dMMR) rectal cancer, achieving a 100% success rate in a clinical trial without the need for surgery or chemotherapy. The trial, presented at the ASCO conference, involved 42 patients who all showed no evidence of disease after treatment. This breakthrough could significantly change the standard of care for this type of bowel cancer.

